KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Advances in Immunotherapy for Breast Cancer.

Sarah Poland, Matheus de Oliveira Andrade Md, Rita Nanda

Oncology (Williston Park) 40(1) 8-15

PMID41701864
PMCIDPMC13352594
DOI10.46883/2026.25921061
发表日期2026-02-17
摘要

摘要

Immunotherapy has transformed the treatment of a variety of malignancies, including breast cancer. Given the unmet clinical need, immunotherapy was first studied in advanced-stage, triple-negative breast cancer (TNBC). The anti-PD-1 agent pembrolizumab plus chemotherapy is approved for both advanced and early TNBC, and data from randomized phase 3 trials in high-risk, early-stage, hormone receptor-positive breast cancer have demonstrated promising efficacy. Ongoing trials aim to identify the most appropriate patients for treatment, amount and timing of immunotherapy needed for optimal outcomes, and ideal combination of therapies to maximize survival while minimizing toxicity. The future of immunotherapy in breast cancer will continue to evolve with the advent of novel immunologic agents. In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。